Design Therapeutics, Inc.
NASDAQ:DSGN
6.49 (USD) • At close December 26, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0.838 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.033 | 0.02 | 0.031 | 0.142 |
| Cost of Revenue
| 0 | 0.151 | 0.143 | 0.138 | 0.137 | 0.143 | 0.139 | 0.135 | 0.122 | 0.113 | 0.096 | 0.082 | 0.031 | 0.012 | 0.004 | 2.708 | 1.914 | 1.061 | 0.377 |
| Gross Profit
| 0 | -0.151 | -0.143 | 0.7 | -0.137 | -0.143 | -0.139 | -0.135 | -0.122 | -0.113 | -0.096 | -0.082 | -0.031 | -0.012 | -0.004 | -2.675 | -1.894 | -1.03 | -0.235 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.835 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -81.061 | -94.7 | -33.226 | -1.655 |
| Reseach & Development Expenses
| 11.876 | 10.365 | 9.658 | 10.874 | 13.257 | 17.064 | 15.73 | 14.255 | 14.304 | 11.295 | 8.759 | 7.337 | 8.539 | 5.027 | 3.875 | 2.708 | 1.914 | 1.061 | 0.377 |
| General & Administrative Expenses
| 4.37 | 4.527 | 4.599 | 4.109 | 5.565 | 5.532 | 5.921 | 5.137 | 4.888 | 4.344 | 4.611 | 3.79 | 2.798 | 2.66 | 1.805 | 1.186 | 0.489 | 0.433 | 0.388 |
| Selling & Marketing Expenses
| 0 | 0.076 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.37 | 4.527 | 4.599 | 4.109 | 5.565 | 5.532 | 5.921 | 5.137 | 4.888 | 4.344 | 4.611 | 3.79 | 2.798 | 2.66 | 1.805 | 1.186 | 0.489 | 0.433 | 0.388 |
| Other Expenses
| 0 | 3.25 | 3.295 | 3.279 | 3.033 | 2.659 | 2.357 | 2.052 | 1.488 | 0.64 | 0.105 | 0.062 | 0.019 | 0.051 | 0.166 | 0.006 | 0.063 | 0.021 | -0.04 |
| Operating Expenses
| 16.246 | 14.892 | 14.257 | 14.983 | 18.822 | 22.596 | 21.651 | 19.392 | 19.192 | 15.639 | 13.37 | 11.127 | 11.337 | 7.687 | 5.68 | 3.861 | 2.383 | 1.463 | 0.623 |
| Operating Income
| -16.246 | -15.043 | -14.4 | -15.121 | -18.822 | -22.596 | -21.651 | -19.392 | -19.192 | -15.639 | -13.37 | -11.127 | -11.337 | -7.687 | -5.68 | -3.861 | -2.383 | -1.463 | -0.623 |
| Operating Income Ratio
| 0 | 0 | 0 | -18.044 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -117 | -119.15 | -47.194 | -4.387 |
| Total Other Income Expenses Net
| 3.207 | 3.25 | 3.295 | 3.279 | 3.033 | 2.659 | 2.357 | 2.052 | 1.488 | 0.64 | 0.105 | 0.062 | 0.019 | 0.051 | 0.166 | 0.006 | 0.063 | 0.021 | -0.04 |
| Income Before Tax
| -13.039 | -11.793 | -11.105 | -11.842 | -15.789 | -19.937 | -19.294 | -17.34 | -17.704 | -14.999 | -13.265 | -11.065 | -11.318 | -7.636 | -5.514 | -3.855 | -2.32 | -1.442 | -0.663 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -14.131 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -116.818 | -116 | -46.516 | -4.669 |
| Income Tax Expense
| 0 | 0 | 0.1 | 2.494 | -0.137 | 0.011 | -2.357 | -2.176 | -1.488 | -0.64 | -0.105 | -0.062 | 0 | 0 | 0 | 0 | 0 | -1.463 | -0.623 |
| Net Income
| -13.039 | -11.793 | -11.105 | -11.842 | -15.789 | -19.937 | -16.937 | -15.164 | -16.216 | -14.359 | -13.16 | -11.065 | -11.318 | -7.636 | -5.514 | -3.855 | -2.32 | -1.442 | -0.663 |
| Net Income Ratio
| 0 | 0 | 0 | -14.131 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -116.818 | -116 | -46.516 | -4.669 |
| EPS
| -0.23 | -0.21 | -0.2 | -0.21 | -0.28 | -0.36 | -0.3 | -0.27 | -0.29 | -0.26 | -0.24 | -0.2 | -0.21 | -0.14 | -0.31 | -0.14 | -0.085 | -0.053 | -0.024 |
| EPS Diluted
| -0.23 | -0.21 | -0.2 | -0.21 | -0.28 | -0.36 | -0.3 | -0.27 | -0.29 | -0.26 | -0.24 | -0.2 | -0.21 | -0.14 | -0.31 | -0.14 | -0.085 | -0.053 | -0.024 |
| EBITDA
| -16.093 | -14.892 | -14.257 | -14.983 | -18.685 | -22.463 | -21.522 | -19.268 | -19.084 | -15.547 | -13.288 | -11.045 | -11.306 | -7.675 | -5.676 | -3.857 | -2.383 | 0.021 | -0.04 |
| EBITDA Ratio
| 0 | 0 | 0 | -17.879 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -116.879 | -119.1 | -47.194 | -4.387 |